18TH ANNUAL MEETING & DINNER
NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS

“PARTICIPATE AND EDUCATE”

October 6 - 8, 2023
Fairmont Hotel, Washington, D.C.
WELCOME TO
THE 18TH ANNUAL MEETING!

Friday through Sunday
October 6 - 8, 2023

As President of the National Alliance of State Prostate Cancer Coalitions, I would like to extend a very warm welcome to all of our attendees, faculty, and sponsors! This is always an exciting, educational, and inspirational weekend of sharing of best practices, learning about state-of-the-art tests and treatments, and networking with each other and with our faculty. Speaking of faculty, we have once again secured the most brilliant minds to engage us, teach us, and provide us with information that we expect you to bring back to your respective constituencies and share with everyone you can, down to the local level.

This weekend we have a Cocktail Reception Friday evening from 6:30 – 9:30 pm - a chance to get together, find old friends, and meet new ones. Saturday morning there will be Breakfast at 8:00 am, then Sessions from 9:00 am to 5:30, then a Cocktail Reception at 6:30 pm followed by a Dinner at 7:30 with an outstanding Speaker and the presentation of Awards. Sunday there will be Breakfast at 8:00 am, and then Sessions from 9:00 am to 3:00 pm, when the Annual Meeting concludes.

We are thrilled that you can join us and avail yourself of a unique experience unlike anything that any other national prostate cancer organization can offer. We are The Alliance!

Respectfully,

Merel Grey Nissenberg

Merel Grey Nissenberg,
President, “The Prostate Cancer Alliance” (NASPCC)
<table>
<thead>
<tr>
<th>SESSION NAME</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>BREAKFAST</td>
<td>8:00 – 8:45</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>I. THE BASICS</td>
<td></td>
</tr>
<tr>
<td>1. Introduction and Welcome</td>
<td>9:00-9:10</td>
</tr>
<tr>
<td>2. Prostate Cancer in 2023</td>
<td>9:10-9:35</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Prostate Cancer Genetics:</td>
<td>9:35-10:00</td>
</tr>
<tr>
<td>Predictive Germline Genetic Testing and Testing After Diagnosis</td>
<td></td>
</tr>
<tr>
<td>4. Androgen Deprivation Therapy and Novel Anti-Androgens</td>
<td>10:00-10:40</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>5. PROSTATEPEDIA Panel Update with:</td>
<td>10:40-11:10</td>
</tr>
<tr>
<td>Andrew Armstrong, MD, MsC; Mark Markowski, MD, PhD;</td>
<td></td>
</tr>
<tr>
<td>Michael Morris, MD; &amp; Daniel Spratt, MD</td>
<td></td>
</tr>
<tr>
<td>MORNING BREAK</td>
<td>11:10-11:15</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>II. LOCALIZED PROSTATE CANCER</td>
<td>11:15-12:00</td>
</tr>
<tr>
<td>6. Active Surveillance, Surgery</td>
<td>11:15-11:30</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Radiation, Focal Therapy</td>
<td>11:30-12:00</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>Q&amp;A</td>
<td>12:00-12:15</td>
</tr>
</tbody>
</table>
LUNCH  12:15-1:15
“The PROMISE Study; Genetics and Prostate Cancer”
12:30-12:45  *Channing Paller, MD Johns Hopkins, Baltimore

III. PSA RECURRENT DISEASE

8. PSMA PET and Theranostics  1:15-1:35  *Michael Morris, MD Memorial Sloan Kettering, New York
9. PSA Persistence and Recurrence: Salvage Therapy  1:35-1:55  *Daniel Spratt, MD Case Comprehensive Cancer Center, Cleveland
10. Evidence-Based Radiotherapy for Prostate Cancer: Review Across the Disease Spectrum  1:55-2:15  *Daniel Song, MD Johns Hopkins, Baltimore

Q&A  2:15-2:30  *All

IV. ADVANCED PROSTATE CANCER

11. Treatment Options and Treatment Sequencing; BAT and New Combinations with Second Generation Anti-Androgens  2:30-3:10  *Mark Markowski, MD, PhD Johns Hopkins, Baltimore
*Andrew Armstrong, MD, MSc Duke Medical Center, Durham, NC

Q&A  3:10-3:30  *All

V. PRECISION MEDICINE IN PROSTATE CANCER:

12. Management of Side Effects of Second Generation Anti-Androgens  3:30-3:50  *Andrew Armstrong, MD, MSc Duke Medical Center, Durham, NC
13. Which Patients Do Well With Anti-Androgens and AR Receptor Therapy  3:50-4:15  *Christopher Barbieri Weill Cornell, NY

Q&A  4:15-4:30  *All

VI. IMMUNO-ONCOLOGY IN PROSTATE CANCER

14. Car-T Cell Therapy and Bi-Specifics  4:30-5:00  *Vivek Narayan, MD, MS University of Pennsylvania, Philadelphia
*Saul Priceman, PhD City of Hope, Los Angeles

15. Vaccine Strategies and Checkpoint Indicators  5:00-5:30  *James L. Gulley, MD, PhD National Institutes of Health
*Evan Yu, MD University of Washington

INTERACTIVE SESSION
DINNER PRESENTATION: “Antibody Drug Conjugates and Prostate Cancer”

Evan Yu, MD

Evan Yu, MD is Section Head of Medical Oncology, Clinical Research Section, at the Fred Hutchinson Cancer Center, and a Professor of Medical Oncology at the University of Washington School of Medicine, in Seattle, Washington

AWARDS PRESENTATION TO FOLLOW

SUNDAY, OCTOBER 8

AGENDA

SESSION NAME                  TIME

BREAKFAST                     8:15-9:00
    Update on the CDMRP         8:30-9:00
                                8:30-9:00
                                8:30-9:00

VII. GENOMICS; AND SOMATIC TESTING

16. General Primer on Genomics; and Somatic Tumor Testing in Prostate Cancer  9:00-9:20
    Q&A                          9:20-9:30
    9:20-9:30

17. New Directions in Radiotherapy; Revolutionizing the Treatment of Prostate Cancer  9:30-9:55
    Q&A                          9:55-10:10
    9:55-10:10

18. Fireside Chat Q&A          10:25-10:40
    Q&A                          10:25-10:40

19. Novel Therapies on the Horizon for Metastatic Prostate Cancer

*Mark Vieth
Senior Vice President, CRD Associates

*MICHAEL SERZAN, MD
Dana Farber (Harvard), Boston

*ALL

*Saul Priceman, PhD
City of Hope, Los Angeles

*Daniel Spratt, MD
Case Comprehensive Cancer Center, Cleveland

*Samuel Denmeade, MD
Johns Hopkins, Baltimore
BREAK  
10:40-10:45

VIII. PERSONAL NEEDS IN PROSTATE CANCER

20. EVERY MAN NEEDS A PROSTATE CANCER PLAN: Billboards Discussion  
10:50-11:10 *Bruce Williams  
11:10-11:20 *Clarence Williamson

ELECTIONS for 2023-2024 Board  
11:20-11:45 Tom Kirk, Special Advisor to the Board

11:45-12:15 *Michael Zaragoza, MD  
*Clarence Williamson, *Paulette Williamson  
*Tony Minter, *Tammie Minter, *David Sauls

LUNCH  
12:15-1:00

22. Report from the Chair of STEERING COMMITTEE  
1:00-1:10 *Thomas Kirk, Chair and Advisory Committee Chairs

23. Family Impact of Prostate Cancer: Daughters  
1:10-1:45 *Jessica Myers, PROSTATEPEDIA Editor  
*LaTanya Patton, Vice President

24. Attendees’ General Discussion  
1:45-2:00 *All Attendees

25. Calendaring and Wrap-Up  
2:00-2:15 *Merel Nissenberg

18th ANNUAL MEETING ADJOURNS
ABOUT NASPCC – “THE PROSTATE CANCER ALLIANCE”

The National Alliance of State Prostate Cancer Coalitions (NASPCC) is a 501(c)(3), not-for-profit organization, with an extensive network and national outreach through many state prostate cancer organizations and individuals. We are an Alliance comprised of many entities, including state prostate cancer coalitions, foundations, associations, and others who are interested in helping to save the lives of men with prostate cancer.

NASPCC – “The Prostate Cancer Alliance” was formed in October 2004 to serve as an umbrella organization in which state prostate cancer organizations could participate and help generate “strength in numbers”. We have become a large critical mass and voice for prostate cancer patients and their families.

We publish PROSTATEPEDIA Magazine (8 times a year) and a weekly PROSTATEPEDIA DIGEST, a compendium of the most current curated articles, abstracts, and press releases. Subscriptions are free and these are sent to 12,000+ people on our Subscription List. The Magazines are archived on our www.naspcc.org website.

We advocate for Informed Decision-Making in prostate cancer, and we disseminate durable, laminated 2-sided education tools for both patients AND for physicians. There are 6 completed Laminates and 5 in queue. See www.prostatecalif.org/patient-guide. We hold an Annual Meeting to enhance education and to share best practices with patients across the country. The resources we disseminate make their way through to the states and reach down through to the local levels, including support groups and individuals who do not participate in those groups.

We actively provide, through our participating organizations: support groups, educational forums, Webinars, Workshops, prostate cancer information, and awareness and educational activities. Our website www.naspcc.org is very dynamic and we have an active Facebook Page “National Alliance of State Prostate Cancer Coalitions” as well.

We advocate for the highest quality of life for prostate cancer patients and their families.
We have an Advisory Board comprised of influential and respected physicians, scientists and researchers.
We are many states strong and growing. We are “The Prostate Cancer Alliance”!

EDUCATIONAL OBJECTIVES

At the conclusion of NASPCC’s 18th Annual Meeting & Gala, attendees should be aware of the basics of prostate cancer; fundamentals of testing (genetic, genomic and other tests and imaging); critical aspects of prostate cancer pathology; risk assessment for treatment planning; fundamentals of treatment for different stages of prostate cancer; new developments in molecular imaging with PSMA; fundamentals of Low-Risk Disease, Focal Therapy, and Active Surveillance; Advanced and untreated metastatic disease, as well as non-metastatic castrate-resistant disease; fundamentals of immunotherapy; fundamentals of recurrence; and how to ensure that patients have appropriate access to optimal care, whether they are treated at an academic center or in a community setting. This information should then enable patients – and those that help them make treatment choices – to make informed, individualized decisions with their physicians.
**Prostatepedia** features informal conversations with doctors, patients, and activists about prostate cancer. Each issue tackles a different topic facing prostate cancer patients today—from how imaging has impacted treatment to dealing with erectile dysfunction after radiation or surgery to the evolving field of immunotherapy.

**Prostatepedia Magazine** (eight times a year) and the weekly **Prostatepedia Digests** became part of NASPCC starting with the August 2020 issue of the magazine.

Here are the most recent 2023 PROSTATEPEDIA Magazine Issues (Please see www.naspcc.org for prior issues):

July - August 2023 - Testing
- Prostatepedia Magazine - Vol 7 No. 4 - Flipping Book format: [https://online.flippingbook.com/view/187941146/](https://online.flippingbook.com/view/187941146/)

May - June 2023 - New Directions in Advanced Prostate Cancer
- Prostatepedia Magazine - Vol 7 No. 3 - Flipping Book format: [https://online.flippingbook.com/view/150884930/](https://online.flippingbook.com/view/150884930/)

March - April 2023 - Imaging
- Prostatepedia Magazine - Vol 7 No. 2 - Flipping Book format: [https://online.flippingbook.com/view/670383721/](https://online.flippingbook.com/view/670383721/)

January - February 2023 - Metastatic Hormone-Sensitive Prostate Cancer
- Prostatepedia Magazine - Vol 7 No. 1 - Flipping Book format: [https://online.flippingbook.com/view/186360576/](https://online.flippingbook.com/view/186360576/)

November - December 2022 - Chemotherapy
- Prostatepedia Magazine - Vol 6 No. 12 - Flipping Book format: [https://online.flippingbook.com/view/736119797/](https://online.flippingbook.com/view/736119797/)

This Fall we will have a Special Edition of PROSTATEPEDIA Magazine on “BLACK MEN AND PROSTATE CANCER”

Please use this link to Subscribe to Prostatepedia: [https://mailchi.mp/c98f8914f351/prostatepedia-sign-up](https://mailchi.mp/c98f8914f351/prostatepedia-sign-up)
NATIONAL ALLIANCE OF STATE PROSTATE CANCER COALITIONS

EXECUTIVE COMMITTEE

Merel Nissenberg, Esq. (California)
President, National Alliance of State Prostate Cancer Coalitions

Merel Grey Nissenberg, Esq. is a medical malpractice attorney in Los Angeles handling cases around the country, and she is President of three non-profits in healthcare: the National Alliance of State Prostate Cancer Coalitions (NASPCC); the California Prostate Cancer Coalition (CPCC), both of which she co-founded; and the Clifton F. Mountain Foundation for Education & Research in Lung Cancer. She is a member of two National Cancer Institute SPORES (one in Prostate Cancer at UCLA, one in Lung Cancer at M. D. Anderson Cancer Center), and she is on the UCLA SPORE Executive Committee. She is also the Advocate for the Canary Foundation/ PASS Trial at Stanford (Prostate Active Surveillance) and is part of a PCORI Grant with UCLA dealing with decision aids in prostate cancer. Additionally, through her consulting group Informed Health Consulting she and her partner help accrue patients to Clinical Trials and also create Patient Ambassador Programs and Roundtables. Merel has been actively involved for almost ten years as one of three national Patient Advocates for the Early Detection Research Network (EDRN) of the National Cancer Institute, handling three of the four Collaborative Groups: GU Cancers, GYN Cancers, and Lung Cancer. In her law practice she has represented many cancer patients and has advocated for them and for their families. Merel is extremely interested in the early detection of cancers when they are still curable and is dedicated to improving the lives of patients, including those asset-undiagnosed.

Anthony Minter (South Carolina)
Treasurer, National Alliance of State Prostate Cancer Coalitions

Anthony Minter has been involved with Prostate Cancer Advocacy since 2012. As a Survivor, he made it his mission to provide support, education and awareness within his community and throughout the nation. Tony is the leader of the Columbia Chapter of UsToo International and a Consumer Advocate for Zero Prostate Cancer. He is also on the Board of Directors of the South Carolina Cancer Alliance. Recently, he has been selected to serve on the Executive Board of the National Alliance of State Prostate Cancer Coalitions (NASPCC) and is the current treasurer. He has participated in numerous health fairs and information sessions concerning prostate cancer and has been a link between the patients, their families and their physician. He is a Certified Professional Executive Coach, specializing in Relationships, Leadership, Career and life. Tony was also selected to be a Consumer Reviewer for the Congressionally Directed Medical Research Program (CDMRP), responsible for screening applications for research grants aimed at finding new treatment therapies, creating better detection tools and decreasing the Prostate Cancer health disparity in men of African descent.

Jan Marfyak (New Mexico)
Secretary, National Alliance of State Prostate Cancer Coalitions

Jan Marfyak is one of the founders of NASPCC, served as its Treasurer, and is currently Secretary. He has been on the Board of Directors since 2004, the year of its organization. Jan served in Wisconsin State government after leaving the University of Wisconsin, and later moved to Washington DC, first at the Department of Justice and later at the Department of Energy. He is a prostate cancer survivor (1975) and is Secretary of the Prostate Cancer Support Association of New Mexico, an active state prostate cancer organization.

Following treatment, Jan volunteered at the Foundation for Urological Disease in Baltimore, MD and later started the Pennsylvania State Prostate Coalition. Jan has been instrumental in helping to start other state prostate cancer organizations and in sharing his knowledge of budget and advocacy issues.

Donald Lynam, PhD (Kentucky)
Director at Large, National Alliance of State Prostate Cancer Coalitions

Don has been active in the prostate cancer community for approximately 20 years, with NASPCC, and before that, Us TOO. He has served on the Board of Directors (BOD), Executive Committee, and Treasurer of NASPCC for the past 9 years. Don is Vice Chairman of KY PCC. He is a past member and Vice Chairman of the BOD of Us TOO, and Chapter Leader of Us TOO of the Bluegrass (Lexington, KY) for the past 15 years.

Don has degrees in Engineering (B.S. and M.S.) from the University of Kentucky and Environmental Health (M.S. and Ph.D.) from the University of Cincinnati. He served 3 years in the US Air Force, as a commissioned officer, primarily at the US Air Force Flight Test Center and Rocket Propulsion Laboratory at Edwards AFB in California. He spent a successful career in the metals and petroleum chemicals industry in engineering and environmental health, retiring as Corporate Vice President.

LaTanya Patton (Missouri)
Vice President, National Alliance of State Prostate Cancer Coalitions

LaTanya currently serves as the President and CEO of Missouri Prostate Cancer Alliance (MoPCA) which she co-founded 2013. In addition to her professional work, she is the primary caregiver for her mother who is stricken with Alzheimer’s disease. LaTanya is a brain aneurysm survivor and supports the University of Kansas Medical Center’s Orthopedic Center of Excellence in treatment and education.

continued on next page
LaTanya Patton continued
Kansas Health System Brain Aneurysm support group.
Prior to Missouri Prostate Cancer Alliance, she worked for Blue Cross and Blue Shield of Kansas City; Heart to Heart International – assigned to the country of Haiti; served as President and CEO of a small minority agency; Vice-President of Community Relations of MAST Ambulance and worked in various capacities for the City of Kansas City Missouri for 16 years including the Health Department before leaving to furthering her professional career.
LaTanya’s community service activities include serving as an Ambassador for American Heart Association, The Mayor’s Commission on AIDS/HIV (TGA), Ivy Community Service and Education Foundation, Swope Ridge Geriatric Center Board of Directors. She serves on the Board of Directors of NASPCC - Director at Large. LaTanya has been an active member of Alpha Kappa Alpha Sorority Incorporated for 34 years and is the immediate past President her chapter.
LaTanya has earned a Bachelor of Science in Business Administration from Lincoln University, Jefferson City, Missouri and is pursuing a Master in Business Administration from the University of Phoenix with an emphasis in organizational development and non-profit leadership. In addition, LaTanya considers herself a consistent leaner and is completing a teaching certification program at Western Bible College in Christian Education.
LaTanya is happily married to Frederick Patton and has two beautiful daughters, Lauren Patton, and Logan Patton. In her spare time, she enjoys reading, shopping, participating community service activities with the sorority, volunteering and traveling with her family.

Thomas Kirk
Invited Member, National Alliance of State Prostate Cancer Coalitions
Tom Kirk has been heavily involved in Patient Advocacy Non-Profit Organizations. He currently serves as the Vice-President of the California Prostate Cancer Coalition (CPCC), which is “A Proud Participant in the National Alliance of State Prostate Cancer Coalitions” (NASPCC). Tom is also an Invited Member of the NASPCC Executive Committee.
Tom Kirk developed the Strategic Plan for NASPCC in 2017 and as Chair of NASPCC’s Steering Committee, he monitors the Plan’s implementation with the NASPCC Committees that were created to move it forward. Tom also serves on the NASPCC Advocacy and Public Policy Committee which, following NASPCC’s 2018 Bone Health Access Initiative (BHI), and the October Bone Health Access Roundtable, prioritized “Step Therapy and Access” as an issue.
In prostate cancer, Tom served as the President and CEO of Us TOO International in suburban Chicago for over 10 years, before moving to California in 2016. He currently works as a Co-Founder of Informed Health Consulting (IHC).
Additionally, Tom worked for over 12 years at the National Alzheimer’s Association headquartered in Chicago. He worked on the Senior Management Team where he was the Vice President of Patient, Family and Education Services. He has also assisted other Residential Care Providers (Mather Life Ways and Belmont Village) develop their Dementia Care Services, and he worked as the Vice President of Operations for Life Care Centers of America’s Garden Terrace Associates managing their specialized Dementia-Specific Long-Term Care Centers and Dementia Care Units. Tom holds an MSSW Degree in Planning and Administration from the University of Wisconsin-Madison.

BOARD OF DIRECTORS 2022-2023

Mary Anderson  
Elizabeth Bridges  
Dave Hulbert  
Crissy Kantor  
Paul Kradel  
Robin Leach  
Harold Pharoah  
David Sauls  
Renee Savickas  
Ronell Showell  
Bruce Williams  
Clarence Williamson  
Darrell Wilson  
Ulysses Wright

North Carolina  
Louisiana  
Minnesota  
New Hampshire  
West Virginia  
Texas  
Nebraska  
Delaware  
Colorado  
Wisconsin*  
Arizona  
Tennessee  
Idaho  
Kansas

*Deceased
“Reaching Thousands of Prostate Cancer Patients and their Families Across the U.S. Since 2004”

MISSION STATEMENT
NASPCC is a nation-wide organization, comprised of state prostate cancer coalitions, dedicated to saving men’s lives and enhancing the quality of life of prostate cancer patents and their families, through awareness and education and the development of a public policy network.

LEADERSHIP
NASPCC has an elected Board of Directors made up of State Representatives, which meets four times a year; and a Standing Executive Committee which meets monthly, composed of the four Officers, an elected Director-at-Large and an Invited Member. Eight Advisory Committees were formed in November 2017 to help accomplish the goals of the Strategic Plan adopted in July 2017. In September 2018, the Executive Committee created a Standing Committee, chaired by Tom Kirk, to monitor and strengthen the progress of these Eight Advisory Committees:

- Advocacy and Public Policy, Chair: Beth Bridges/Paul Kradel
- Annual Meeting Committee, Chair: Merel Grey Nissenberg
- Budget Committee, Chair: Tony Minter
- Communications Committee, Chair: Renee Savickas/Fran Franklin
- Education and Awareness Committee, Chair: Clarence Williamson
- Fundraising Committee, Chair: Merel Grey Nissenberg
- Medical Advisory Committee, Chair: Michael Zaragoza, MD
- State Coalition Development Committee, Chair: Beth Bridges/David Sauls

REACHING PATIENTS AND THEIR FAMILIES
NASPCC supports the development of state prostate cancer organizations, each of which is comprised of patient networks and support groups. NASPCC through its Annual Meeting, webinars and other activities shares prostate cancer information with all of its participating state prostate cancer organizations, and this material is then disseminated to patients and their families, demonstrating the breadth and depth of our reach. NASPCC also helps equip patients and their families to actively engage in the prostate cancer cause.

THE NASPCC ANNUAL MEETING
The Annual Meeting pulls together leaders in the rapidly developing field of prostate cancer — patients and families, researchers, practitioners, and people interested in the disease — who want to share, learn and lead. The patient community is unique and the contemporary overview in the Take Home Messages from the Annual Meeting allows them to become empowered to do things locally. NASPCC creates support and a forum to enrich and rejuvenate these individuals and state organizations.
ANDREW ARMSTRONG, MD, MSc
2023-2024 NASPCC Honoree

Dr. Andrew John Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology, and Cancer Biology at Duke and is Director of Research for the Duke Cancer Institute’s Center for Prostate And Urologic Cancer. Dr. Armstrong received his B.S.E. from Duke University in 1996, his M.D. from the University of Virginia in 2000, and his M.Sc. from Johns Hopkins in 2008. His Fellowship took place in the Division of Oncology/Hematology at Johns Hopkins University school of Medicine. Dr. Armstrong is an internationally recognized medical oncologist concentrating on experimental therapeutic and development of biomarkers in genitourinary cancers, especially prostate cancer. He led the development of enzalutamide and its FDA approval for men with metastatic prostate cancer and helped develop a number of other experimental therapies such as AR inhibitors, immunotherapies, and anti-angiogenic agents. He is involved in multiple Phase 1-4 Clinical Trials for men with prostate cancer, such as ARCHES and ENZAMET, and has received numerous awards for his work. Dr. Armstrong devotes over half of his time to understanding how prostate cancer spreads and how it resists therapies. His goal is to develop treatments that prolong and improve the quality of life for prostate cancer patients. Dr. Armstrong has authored over 160 peer-reviewed publications, as well as chapters, reviews, and abstracts. He has presented several Webinars for NASPCC and has led the way in discovery science in genitourinary cancers.

MICHAEL MORRIS, MD
2023-2024 NASPCC Honoree

Dr. Morris is a prostate cancer specialist, clinical investigator, full member, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Morris has led numerous clinical trials but has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on tumor and bone-directed radiopharmaceuticals for prostate cancer. He was part of the leadership team that developed Lu-177 PSMA-617, which is now FDA approved for men with advanced prostate cancer. He has a research focus interest in developing novel imaging technologies for metastatic prostate cancer and in credentialing imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and prostate-specific imaging technologies such as PSMA-directed PET imaging. In addition, he is the Medical Director of the Prostate Cancer Clinical Trials Consortium. He is Special Advisor to the Director of the National Cancer Institute, where he co-leads the Clinical Trials Innovation Unit, a new joint NCI/FDA collaborative clinical trials vehicle. He has long had an interest in novel methods of implementing prostate cancer clinical trials, and utilizing telehealth to reduce barriers to expertise, clinical care, and investigational studies.
JAMES WEST SPIRIT AWARD

James West
Renee Savickas, Awardee

Renee Savickas is Vice President and Director of Early Detection and Awareness Programs for the Prostate Conditions Education Council and has been the Colorado representative to NASPCC for many years. Renee has been a Member of the Board of Directors of NASPCC since January 2016 and is co-chair of NASPCC's Communications Committee, one of the 8 Advisory Committees that help run the organization; and in that capacity she serves as Newsletter Editor. She is also Co-Chair of the Prostate Cancer Task Force for the Colorado Cancer Coalition. Last year Renee, along with her Communications Committee colleagues, streamlined the format for the NASPCC Newsletter – called “The Blueprint”, and she ensures that each edition is produced and sent out to the membership on a quarterly basis, before it is then archived on the NASPCC website. Renee cares about the prostate cancer representatives with whom she works at NASPCC, and it shows. Despite her busy schedule, Renee cheerfully carries out her Committee responsibilities and is a spirited advocate for both the Newsletter and for NASPCC. We award RENEE SAVICKAS the JAMES WEST SPIRIT AWARD! Congratulations, RENEE!

JAN MARFYAK LEADERSHIP AWARD

Jan Marfyak
Michael Zaragoza, MD, Awardee

Dr. Michael Zaragoza is a urologist in private practice in Dover, Delaware, and is President of both the Delaware Urological Society and the Delaware Prostate Cancer Coalition. When NASPCC first helped start the Delaware Prostate Cancer Coalition a very long time ago, Dr. Zaragoza’s father, Ralph Zaragoza, MD, also a practicing urologist, was its first President. Michael took over the DPCC Presidency from his father and has developed it into one of the most active prostate cancer organizations in NASPCC. DPCC puts on awareness and educational events several times a year with inventive and exciting formats. His leadership has led to better awareness of prostate cancer, and to improved education about testing, diagnoses, treatment modalities, and quality of life for prostate cancer patients and their families. Dr. Zaragoza also leads our Medical Advisory Committee, one of the 8 Advisory Committees that help run our organization. Last year at the 17th Annual Meeting Dr. Zaragoza moderated a Panel on quality of life, ED, and emotional issues. This year he will moderate another Panel on the same issues which will also include wives. Dr. Zaragoza leads the Delaware Prostate Cancer Coalition with a strong enthusiasm for its mission, and with ideas and events to implement that mission - even with his incredibly busy schedule. NASPCC awards him the JAN MARFYAK LEADERSHIP AWARD, named in honor of our co-founder, Jan Marfyak. Congratulations, MICHAEL!
Christopher Barbieri, MD, PhD
Associate Professor of Urology & Urologic Oncology, Weill Cornell
Christopher Barbieri, MD, PhD is Associate Professor of Urology, Associate Professor of Cell and Developmental Biology, and the Peter M. Sacerdote Distinguished Associate Professor in Urologic Oncology at Weill Cornell Medicine and NewYork-Presbyterian Hospital. His clinical practice focuses on prostate cancer, and his long-term goal is using molecular information to improve the care of prostate cancer patients. Dr. Barbieri received his undergraduate degree from Dartmouth College and then attended Vanderbilt University School of Medicine, where he obtained both his MD and PhD degrees. He then completed both his Urology Residency and Urologic Oncology Fellowship at Weill Cornell Medical College. Dr. Barbieri's research focuses on improving molecular classification of prostate cancer and identifying novel drivers, defining the signaling pathways and biology underlying distinct subtypes of the disease, and exposing new therapeutics avenues. His work has led to recognition and awards from the Prostate Cancer Foundation, AACR, AAGUS, Urology Care Foundation, SBUR, SUO, and Damon Runyon Cancer Research Foundation, and election to ASCI.

Andrew J. Armstrong, MD, MSc
Medical Oncologist, Duke University School of Medicine
Dr. Andrew J. Armstrong is a board-certified medical oncologist at Duke University with a focus on genitourinary malignancies -- prostate, kidney, bladder, and testicular cancers. He is also a clinical and translational researcher focused on drug development and biomarker studies in prostate and kidney cancer. This research includes prognostic and predictive biomarkers, circulating tumor cell biology, and how cancer spreads (metastasis). He oversees multiple clinical trials of new therapies for patients ranging from new hormonal and chemotherapies to new immunotherapies, and molecularly targeted agents. Dr. Armstrong received his MD from the University of Virginia in 2000 and trained at the University of Pennsylvania and at Johns Hopkins in Baltimore.

Samuel Denmeade, MD
Professor of Oncology and Urology, &Director of the Genitourinary Oncology Division of the Kimmel Cancer Center, Johns Hopkins
Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University; completed his residency at the University of Chicago; and performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development.
investigational studies. of implementing prostate cancer clinical trials, and utilizing clinical trials vehicle. He has long had an interest in novel methods. Director of the National Cancer Institute, where he co-leads the Cancer Clinical Trials Consortium. He is Special Advisor to the PET imaging. In addition, he is the Medical Director of the Prostate and prostate-specific imaging technologies such as PSMA-directed the Prostate Cancer Working Group 2 and 3 Consensus Criteria, imaging technologies for metastatic prostate cancer and in cancer. He has a research focus interest in developing novel which is now FDA approved for men with advanced prostate was part of the leadership team that developed Lu-177 PSMA-617, and bone-directed radiopharmaceuticals for prostate cancer. He Medicine. In the field of therapeutics, he has focused on tumor biology at Georgetown University School of Medicine. He completed a residency in internal medicine at Columbia University, followed by a medical oncology fellowship at Johns Hopkins Hospital. Dr. Markowski is a board member and secretary for the Genito-Urinary Multidisciplinary D.C. Regional Oncology Project (GUMDROP).

Dr. Markowski previously served as a research associate at the Lombardi Comprehensive Cancer Center at Georgetown University. His research interests focus on early phase drug development for prostate cancer, and anti-inflammatory agents and cancer incidence. Dr. Markowski is currently conducting research with funding from a Postdoctoral Training Award from the Department of Defense's Prostate Cancer Research Program, and a Young Investigator Award from the Prostate Cancer Foundation, which focuses on new treatment strategies for prostate cancer patients and credentialing these treatments for advancement to clinical trials.

Dr. Michael Morris is a proton therapy specialist, clinical investigator, full member, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York and performed his internship and residency in Internal Medicine at Columbia Presbyterian Medical Center. He then completed his medical oncology fellowship at Memorial Sloan Kettering Cancer Center.

Dr. Morris has led numerous clinical trials but has a particular research focus on targeted therapy for prostate cancer, especially those that bridge the fields of Medical Oncology and Nuclear Medicine. In the field of therapeutics, he has focused on tumor and bone-directed radiopharmaceuticals for prostate cancer. He was part of the leadership team that developed Lu-177 PSMA-617, which is now FDA approved for men with advanced prostate cancer. He has a research focus interest in developing novel imaging technologies for metastatic prostate cancer and in credentialing imaging biomarkers. He has been a co-developer of the Prostate Cancer Working Group 2 and 3 Consensus Criteria, and prostate-specific imaging technologies such as PSMA-directed PET Imaging. In addition, he is the Medical Director of the Prostate Cancer Clinical Trials Consortium. He is Special Advisor to the Director of the National Cancer Institute, where he co-leads the Clinical Trials Innovation Unit, a new joint NCI/FDA collaborative clinical trials vehicle. He has long had an interest in novel methods of implementing prostate cancer clinical trials, and utilizing telehealth to reduce barriers to expertise, clinical care, and investigational studies.

Jessica Myers
Editor, PROSTATEPEDIA
Jessie Myers is a Silicon Valley-based Realtor, long-time prostate cancer patient advocate, and the oldest daughter of patient favorite Dr. Snuffy Myers. She’s the voice of Prostatepedia, a digital magazine that goes out to patients and caregivers in the United States, Canada, Europe, India, Australia, and New Zealand. She has completed over 500—and counting!—interviews with doctors, advocates, patients, and caregivers about all aspects of prostate cancer. Jessie attended the University of Pennsylvania and is the former head of the University of Pennsylvania Silicon Valley Alumni Club. She is grateful to be a part of the prostate cancer community and humbled by both patient and doctor stories alike.

Vivek Narayan, MD, MS
Dr. Vivek Narayan, MD MSCE is an Assistant Professor of Medicine in the Division of Medical Oncology at the University of Pennsylvania’s Abramson Cancer Center. His clinical and research interests are specifically focused on the care of patients with advanced prostate cancer and kidney cancer. He serves as principal investigator on several therapeutic oncology clinical trials, including multiple investigator-initiated studies and immune and cellular therapies for advanced prostate cancer. He additionally seeks to improve survivorship care for patients with cancer, including the evaluation and management of cardiac toxicities of cancer therapies for prostate and kidney cancers. Dr Narayan’s early career achievements have been nationally recognized, with selection as the 2018 AUA Urology Care Foundation Outstanding Graduate Scholar Award, as well as a recipient of the 2018 Prostate Cancer Foundation Young Investigator Award. He has received research funding from the American Cancer Society, American Urological Association, and the Prostate Cancer Foundation.

Channing Paller, MD
Associate Professor of Oncology, Johns Hopkins
Dr. Channing J. Paller is an associate professor of oncology and Director of Prostate Clinical Research at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. Her research focuses on developing improved, targeted treatments to extend survival and improve quality of life for prostate cancer patients. She has a passion for exploring genetic biomarkers and early phase trials for prostate cancer. Dr. Paller has received funding from NCI, Prostate Cancer Foundation, Department of Defense, Billie Marcus Foundation, and other foundations.

continued on next page
Saul Priceman, MD  
Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Los Angeles  
Dr. Saul Priceman is an assistant professor in the T Cell Immunotherapy Program at City of Hope and a trained tumor immunologist with expertise in T cell biology and cancer immunotherapy. He is developing chimeric antigen receptor (CAR)-based T cell immunotherapy primarily for solid cancers, with a strong focus on metastatic disease in breast, prostate and pancreatic cancer. Dr. Priceman received his B.S. in microbiology at University of California Santa Barbara, and his Ph.D. in molecular and medical pharmacology at University of California Los Angeles. He is a principal investigator on a Prostate Cancer Foundation Young Investigator award, a co-principal investigator on a Prostate Cancer Foundation Challenge Award and a principal investigator on a National Comprehensive Cancer Network Young Investigator award, leading the development of HER2-specific CAR T therapy for metastatic breast cancers and working with his team optimizing new CAR T cell therapies for various other solid cancers. Dr. Priceman is committed to rapidly advancing potentially paradigm-shifting immunotherapy on behalf of cancer patients. His overarching goal is to develop a range of effective immunotherapies for solid cancers, based on the powerful CAR T cell platform, with the knowledge that any single therapy will not likely provide durable responses in advanced disease.

Michael Serzan, MD  
Medical Oncologist, Dana Farber Cancer Institute  
Dr. Michael Serzan is a Medical Oncologist at the Dana-Farber Cancer Institute and Instructor of Medicine at Harvard Medical School. Dr. Serzan received his undergraduate degree from Boston College and medical degree from Rutgers, trained in Internal Medicine at Medstar Georgetown University, and completed his fellowship in Medical Oncology at the Lombardi Comprehensive Cancer Center. His clinical practice as a genitourinary medical oncologist focuses on caring for patients with prostate, kidney, bladder and testicular cancer. Dr. Serzan also conducts clinical research focused on understanding the impact of germline genetics testing for men with prostate cancer and investigating mechanisms of immune checkpoint inhibitor treatment resistance.

Daniel Y. Song, MD  
Professor, Johns Hopkins Medicine  
Dr. Daniel Song is Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-Director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. He received his MD from the Medical College of Georgia, and trained at Johns Hopkins University School of Medicine. Dr. Song is a reviewer and examiner for the American Board of Radiology. He has co-authored consensus guidelines on low-dose-rate brachytherapy, stereotactic body radiation therapy, and image-guided robotic brachytherapy. He also served as Faculty for NASPCC’s 15th Annual Meeting in October 2019.

Daniel Spratt, MD  
Case Comprehensive Cancer Center  
Dr. Daniel Spratt is the Chairman and Professor of Radiation Oncology at University Hospitals (UH) Seidman Cancer Center and Case Western Reserve University (CWRU). He obtained his medical degree from Vanderbilt Medical School and completed his radiation oncology residency at the University of Michigan until April 2021 when he joined UH and CWRU. He served as the Vice Chair in the Department of Radiation Oncology and Chair of the Genitourinary Clinical Research Team at the University of Michigan until April 2021 when he joined UH and CWRU. 
Dr. Spratt is an international expert in the management of prostate cancer and the development and validation of prognostic and predictive biomarkers. He has published over 300 peer-reviewed manuscripts and runs a National Institute of Health-funded translational lab. He serves as the Chair for NRG Oncology’s Intact Prostate Cancer Subcommittee, and for the National Cancer Institute’s Genitourinary Steering Committee. He is the PI of numerous national and international randomized clinical trials in prostate and bladder cancer, and has mentored over 40 students and faculty.
Mark Vieth
Senior Vice President, CRD Associates

Mark D. Vieth, Senior Vice President, joined the firm in 2002 and manages a diverse portfolio of clients in several practice areas, including public health and medical research. Mark currently serves as the coordinator for several national coalitions, including the Defense Health Research Consortium. He has specialized in bringing diverse associations, foundations, institutions of higher education and other stakeholders together to advocate for common objectives. He has helped clients secure federal funding, build new partnerships with federal agencies and mobilize grassroots to advocate for legislation pending in Congress. He also has developed a niche in helping clients who have never interacted with Congress or federal agencies launch sophisticated and focused federal government relations strategies.

Prior to joining CRD Associates, Mark served for 14 years as a professional staff member in the House of Representatives. As Chief of Staff for Congressman Robert A. Borski (D-PA), Mark worked extensively on legislative issues and projects of importance to one of the nation’s major medical research clusters in Philadelphia. Mark is also past President and current Treasurer of the Pennsylvania Society of Washington, D.C. He earned his B.A. in international relations from Syracuse University.

Evan Y. Yu, M.D.
Professor & Genitourinary Medical Oncologist at the University of Washington & Fred Hutchinson Cancer Center

Evan Y. Yu, M.D., is a medical oncologist specializing in GenitoUrinary malignancies, specifically prostate, bladder and testicular cancer treatment and research. He is the Section Head for Cancer Medicine, Clinical Research Division at the Fred Hutchinson Cancer Center. He also serves as the Medical Director for Clinical Research at the Fred Hutchinson Cancer Consortium. He is a Professor at the University of Washington and Fred Hutchinson Cancer Center. He is the institutions Principal Investigator for the National Cancer Trials Network Lead Academic Performance Site (LAPS) Grant, SWOG, and ECOG/ACRIN. Dr. Yu is also the Core Director for the Pacific Northwest Prostate Cancer SPORE and co-PI of the DoD Prostate Cancer Clinical Trials Consortium for his institution. He graduated Alpha Omega Alpha from the University of Washington School of Medicine. His research focuses on testing the next wave of novel molecular targeted therapies and immunotherapy techniques, with a complementary focus on imaging biomarkers. Previously, he served as a Hematology/Oncology Fellowship Program Director for a decade at the Fred Hutchinson Cancer Research Center. He has regularly been voted a “Top Doctor” by Castle Connolly, U.S. News and World Report, Seattle Magazine, and Seattle Met magazine. He has served for many years on the National Cancer Institute Genitourinary Cancers Steering Committee and is currently the Co-Chair for the National Cancer Institute Prostate Cancer Task Force. Dr. Yu has held various leadership/committee roles within ASCO, AACR, AACI, and also serves as a senior editor for Clinical Cancer Research and Uro-Today.

Michael Zaragoza, MD
Urology Associates, Dover, Delaware; President, Delaware Urological Association; & President, Delaware Prostate Cancer Coalition

Dr. Zaragoza obtained his undergraduate degree from Dartmouth College (1983) and MD from Jefferson Medical College (1987). He completed his Urology residency at the University of Michigan (1993), and has been employed in a group private practice, Urology Associates for Delaware, in Dover, Delaware since 1993.

His current academic appointments include Clinical Assistant Professor of Surgery (Urology) at Drexel University College of Medicine, and Clinical Assistant Professor of Surgery at the Philadelphia College of Osteopathic Medicine. Dr. Zaragoza presently serves as President of the Delaware Urological Society and as President of the Delaware Prostate Cancer Coalition (DPCC). He joined his urologist father Ralph Zaragoza (former DPCC president) in 1993, and they practiced together for 8 years.
NASPCC would like to thank the following sponsors for their support:

- Bayer
- Pfizer
- Blue Earth Diagnostics (A Bracco Company)
- Janssen Oncology (Pharmaceutical Companies of Johnson & Johnson)
- Lantheus
- Novartis
- AstraZeneca
- Exelixis
- Merck
- Foundation Medicine
- Sumitomo Pharma
- Promise